Skip to content

Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation

Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation

Status
Withdrawn
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00608231
Enrollment
0
Registered
2008-02-06
Start date
2008-01-31
Completion date
2012-01-31
Last updated
2014-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dystonia, Essential Tremor, Parkinson's Disease

Brief summary

To test the hypothesis that sedation induced by Dexmedetomidine at levels appropriate for awake, DBS surgery has no significant effect on electrophysiological parameters of DBS micro-electrode recordings

Detailed description

Deep brain stimulator (DBS) implants are used in the treatment of medically refractory movement disorders such as Parkinson's disease, essential tremor and dystonia. Because of the uniqueness of each individual brain, the surgery to implant a DBS electrode requires detailed anatomic and physiological information for each patient. The anatomic data is obtained before surgery via a Magnetic Resonance Imaging (MRI) scan of the patient's brain. Physiological data is obtained during the operation via micro-electrode recording of the patient's brain and neurological examination of the patient. Therefore, DBS surgery can be uncomfortable to patients, as it can be very time consuming and requires the patient to be awake and attentive. The specific aims of this project are: 1. To test the hypothesis that sedation induced by Dexmedetomidine at levels appropriate for awake, DBS surgery has no significant effect on electrophysiological parameters of DBS micro-electrode recordings. 2. To test the hypothesis that sedation induced by Dexmedetomidine at levels appropriate for awake, DBS surgery have no significant effects on neurological findings and/or patient cooperation during neurological examination.

Interventions

DRUGDexmedetomidine Hydrochloride Infusion

Dexmedetomidine Hydrochloride Infusion(0.5-1.0 mg/kg)intravenous over 10 minutes with dose adjustment for goal Richmond Agitation and Sedation Scale of -1 During deep brain stimulator implantation surgery

DRUGNormal Saline

Normal Saline intravenous over 10 minutes during deep brain stimulator implantation surgery

Sponsors

Vanderbilt University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Any patient who has agreed to undergo DBS implantation.

Exclusion criteria

* Patients who fail recommendation for DBS surgery discussed in Vanderbilt University Movement Disorder Clinical Conference. * Patients not consented for DBS surgery. * Patients or legal guardians not able to provide informed consent.

Design outcomes

Primary

MeasureTime frame
Micro-electrode RecordingsIntra-operative

Secondary

MeasureTime frame
Neurological Exam FindingsIntra-operative

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026